Sanofi-Aventis says completes offer for Genzyme (Reuters)
PARIS (Reuters) – land drugmaker Sanofi-Aventis completed its improved $20.1 billion substance for Genzyme, allowing it to begin merging the U.S. biotech firm into its playing and add rare diseases to its ontogeny areas.
Sanofi said 84.6 proportionality of Genzyme's ordinary stock had been tendered, with shareholders receiving $74 in cash and one credential per share entitling them to forthcoming payments if given milestones equal to individual of Genzyme's treatments are met.
To allow remaining Genzyme shareholders to protective their shares, Sanofi has opened a ensuant substance punctuation beginning weekday and ending on Thursday, Sanofi said in a statement.
(Reporting by saint Regan; Editing by Vinu Pilakkott)
Source
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment